DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo

Background: Peptide receptor radionuclide therapy (PRRT) increases progression-free survival and quality of life of neuroendocrine tumor (NET) patients, however complete cures are rare and dose-limiting toxicity has been reported. PRRT induces DNA damage of which DNA double strand breaks (DSBs) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuvers, Thom G.A., Verkaik, Nicole S., Stuurman, Debra, de Ridder, Corrina, Groningen, Marian C. Clahsen-van, de Blois, Erik, Nonnekens, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283055/
https://www.ncbi.nlm.nih.gov/pubmed/37351169
http://dx.doi.org/10.7150/thno.82963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283055/
https://www.ncbi.nlm.nih.gov/pubmed/37351169
http://dx.doi.org/10.7150/thno.82963

Ejemplares similares